Immune biomarkers and response to checkpoint inhibition of BRAF^V600 and BRAF non-V600 altered lung cancers.

ABSTRACT:

Background

While 2-4% of lung cancers possess alterations in BRAF, little is known about the immune responsiveness of these tumours.

Methods

Clinical and genomic data were collected from 5945 patients with lung cancers whose tumours underwent next-generation sequencing between 2015 and 2018. Patients were followed through 2020.

Results

In total, 127 patients with metastatic BRAF-altered lung cancers were identified: 29 tumours had Class I mutations, 59 had Class II/III alterations, and 39 had variants of unknown significance (VUS). Tumour mutation burden was higher in Class II/III than Class I-altered tumours (8.8 mutations/Mb versus 4.9, P < 0.001), but this difference was diminished when stratified by smoking status. The overall response rate to immune checkpoint in

SUBMITTER: Murciano-Goroff YR 

PROVIDER: S-EPMC8927094 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature